NEW YORK, NY / ACCESSWIRE / November 6, 2019 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of FibroGen, Inc. ("FibroGen" or "the Company") (NASDAQ:FGEN). Investors who purchased FibroGen stock are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/fgen.
The investigation concerns whether FibroGen and certain of its officers and/or directors have violated federal securities laws.
On November 4, 2019, Plainview LLC ("Plainview") published a report questioning the safety of Fibrogen's lead product candidate, Roxadustat, and describing the Company as the next "biotech blow-up." The Plainview report asserted that the FibroGen was "mysteriously unforthcoming" and misleading investors with regards to the safety and efficacy of Roxadustat. On this news, Fibrogen's stock price fell $3.01 per share, or 7.52%, to close at $37.01 per share on November 4, 2019.
If you are aware of any facts relating to this investigation, or purchased FibroGen shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/fgen. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | [email protected]
SOURCE: Bronstein, Gewirtz & Grossman, LLC